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Abstract  
Background: Cogan`s syndrome (CSy) is a very rare autoimmune disorder, mainly affecting 
the inner ear and the eye, and is associated with inflammatory bowel disease 
(IBD). Materials and methods: This was a European Crohn's and Colitis Organization (ECCO) 
retrospective observational study, performed as part of the CONFER project. A call to all 
ECCO members was made to report concomitant CSy and IBD cases. Clinical data were 
recorded in a standardized questionnaire.  Results: This international case series reports on 
22 concomitant CSy-IBD cases from 14 large medical centers. Mean duration of IBD until 
diagnosis of CSy was 8.7 years (range 0.0-38.0), and mean age at CSy diagnosis was 44.6 
years (range 9.0-67.0). 6 patients had an underlying ulcerative colitis (UC), 16 Crohn`s 
disease (CD). 11 patients (50%) had active disease at CSy diagnosis. 16 patients were under 
IBD treatments at the time of CSy diagnosis, of whom 6 (27.3%) were on anti-TNF. 7 out of 
10 patients, who were treated for CSy with immunomodulators (mostly with 
corticosteroids), demonstrated at least partial response. Conclusion: This is the largest CSy-
IBD case series so far. Although CSy is considered to be an autoimmune disease and is 
associated with IBD, immunomodulatory IBD maintenance treatment and even anti-TNF 
therapy do not seem to prevent disease onset. Moreover, IBD disease activity does not seem 
to trigger CSy. However, vigilance may prompt early diagnosis and directed intervention with 
corticosteriods at inception may potentially hinder audiovestibular deterioration. Finally, 
vigilance and awareness may also offer a better setting to study the pathophysiological 
mechanisms of this rare, but debilitating phenomena. 
 
Keywords: Cogan`s syndrome, inflammatory bowel disease, Crohn`s disease, ulcerative colitis 
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Introduction 
Cogan`s syndrome (CSy) is a very rare autoimmune disorder, [1] which affects the inner ear 
and the eyes. [2] Its typical manifestation has been first described in the 1940s. [3] The 
mainstay of its clinical diagnosis are audiovestibular symptoms resembling Meniere`s 
disease and ocular inflammation such as interstitial keratitis. [4] In up to 70% of patients, 
other systemic manifestations such as arthralgia, fever or myalgias are observed with aortitis 
as the most complicating form. [5] Given the variable onset of symptoms, the possibility of 
atypical subtypes and the lack of specific laboratory tests, the diagnosis is often challenging, 
although cases with calcification and narrowing of the vestibular labyrinth and the cochlea 
on MRI have been recently described. [6,7] Despite its very rare incidence, more than 100 
cases have been published in the literature giving increasing insights into different clinical 
manifestations and disease pathophysiology. [8] 
As it is known from several autoimmune disorders, CSy shows an association with 
inflammatory diseases. Interestingly an assocation between CSy and inflammatory bowel 
diseases (IBD) such as Crohn`s disease (CD) and ulcerative colitis (UC) has been described in 
few patients. [7,9-16] Due to systemic manifestations in both CSy and IBD and the 
challenging diagnosis of CSy, diagnosing CSy in IBD patients seems to be difficult, in 
particular. Hitherto, a total of 13 patients with both CSy and IBD have been reported. [7,9-
16] Moreover, very little is known about the underlying pathophysiological mechanism. 
Herein, we report a case series of 22 patients suffering from both IBD and CSy. Given the 
large study population and the inclusion of patients from a total of 14 international large IBD 
centers, this systematic case series represents a significant contribution to the knowledge 
about this disease and may reveal a possible pathophysiological association between the 
two autoimmune-mediated diseases CSy and IBD. 
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MATERIALS & METHODS 
Study design  
This European Crohn's and Colitis Organization (ECCO) observational multicenter study 
retrospectively collected cases across the world through the CONFER (COllaborative 
Network For Exceptionally Rare case reports) project. The CONFER project was initiated by 
ECCO in order to specifically identify and report together rare IBD disease associations, 
which otherwise get seldom reported due to their exceptional rarity. Briefly, the CONFER 
methodology comprised of selecting a topic worthy of investigation out of case proposals 
submitted by ECCO members. Once a specific IBD disease association was selected by a 
steering committee as CONFER project (Cogan`s syndrome and IBD association in the case of 
the present study), ECCO launched a call to identify similar cases encountered by IBD 
physicians worldwide.  
The call to physicians was made through announcements in the ECCO annual congress and in 
National IBD meetings across Europe and during several International IBD meetings. In 
addition, the call for similar cases was disseminated by direct emails to all ECCO members 
and affiliated physicians and on the ECCO website and in the ECCO eNews. Physicians were 
then prompted to report their case to the CONFER database using a pre-determined 
standardized Case Report Form (CRF). The call for the present case-series was entitled 
"Cogan`s syndrome in patients with IBD". 
 
Patients and procedures 
All adult IBD patients (age > 16 years) with CSy diagnosis throughout the course of IBD or 
prior to its diagnosis were eligible for inclusion in this study. CSy diagnosis was made based 
on clinical presentation according to prior case reports and reviews. [1,17] Data were 
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collected by a CRF, which was divided into two main sections. Section 1 included patient 
(epidemiological data, past medical history, alcohol consumption/smoking, family history) 
and disease (IBD subtype, date of diagnosis, Montreal classification, extraintestinal 
manifestations and IBD treatment) characteristics.  Section 2 included a description of CSy 
with regards to diagnosis: IBD treatment at CSy diagnosis, CSy related symptoms and 
treatments (including cochlea implantation and treatment outcome). Relevant laboratory 
tests were also recorded.   
 
Statistics        
For the statistical analysis, the IBM Software SPSS Statistics Version 22.0.0 (2013 SPSS 
Science, Inc., Chicago, IL) was used.  
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RESULTS 
Patients` background information 
We identified a total of 22 patients from 14 medical centers across the world. 16 patients 
had CD and 6 patients UC. 4 of the 6 UC patients had a pancolitis (Montreal classification E3, 
66.7%), while most of the CD patients showed either ileal (7 patients, 43.8%) or ileocolonic 
(6 patients, 37.5%) disease localisation. Mean age at enrolment was 46.6 years (range 19.0-
74.0) with a mean age at IBD diagnosis of 34.7 years (range 1.0-59.0). 13 were female 
(59.1%), 18 patients were Caucasians (85.7%) and 2 patients (9.1%) had a positive family 
history for IBD with 1 patient reporting a mother with UC and two siblings with CD and 
another patient reporting a sister with CD. Only 3 patients (13.6%) were current smokers, 
while 4 reported to have smoked in the past with a mean cessation time of 15.8 years (3.0-
29.0) at study inclusion. Prior reported IBD treatments mainly consisted of 5-aminosalicylic 
acid (5-ASA) (17 patients, 77.3%), systemic steroids (13 patients, 59.1%) and azathioprine/6-
MP (AZA/MP) (12 patients, 54.4%). A total of 9 patients (40.9%) received at least one dose of 
anti-TNF therapy. 8 patients (36.4%) underwent prior surgery (proctocolectomy in UC, 
partial ileal or jejunal resection and rectal abscess drainage). Patients` characteristics are 
shown in table 1. 4 of the patients had been reported previously in a case series 
investigating the association between CSy and IBD. [9] CSy disease characteristics are 
summarized in table 2. 
 
Cogan`s syndrome and IBD 
All diagnoses of CSy (n=22) were made after IBD was diagnosed. Mean duration of IBD until 
diagnosis of CSy was 8.7 years (0.0-38.0) with a mean age at diagnosis of 44.6 (range 9.0-
67.0). Mean time from first hearing impairment until CSy diagnosis was 1 year (range 0-15), 
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indicating a significant duration of uncertainty before CSy diagnosis. Indeed, in only 8 
patients (36.4%) diagnosis could be definitely made, while in thirteen patients diagnosis was 
probable and in 1 patient remained uncertain. 11 patients (50%) had active disease at CSy 
diagnosis and a total of 16 patients (72.7%) were currently under IBD treatment (table 2). 
The most frequently reported therapies were: 5-ASA (8 patients, 36.4%), AZA/MP (3 
patients, 13.6%) and systemic steroids (2 patients, 9.1%). A total of 6 patients (27.3%) were 
on anti-TNF treatment with median time interval between first anti-TNF administration and 
first audiovestibular or ocular symptoms of 19.5 months (range 4.7-46.0). Median time 
interval to CSy diagnosis was 24.2 months (23.0-47.0). Diagnosis of CSy was made based on 
ORL evaluation, audiometry, ophthalmology evaluation and cranial imaging. 9 patients 
(40.9%) reported audiovestibular symptoms first, while in 6 patients (27.3%) ocular 
involvement occured first. 2 patients (9.1%) reported prodrome symptoms of viral infection 
preceding onset of CSy. Among the most frequently reported CSy symptoms were those 
related to the audiovestibular system with tinnitus, impaired hearing or hearing loss even to 
the point of bilateral deafness, and vertigo. Ocular symptoms were reported in 9 patients 
with most of them suffering from interstital keratitis. Other systemic symptoms such as 
headache, arthralgias, dizziness or fatigue were also frequently reported, while neurologic 
deficits were very rare with hemiparesis and nystagmus in only 1 patient. In addition, only 1 
patient reported vascular complications (such as aortitis). None of the ongoing 
audiovestibular or neurologic symptoms were attributed to prior or concomitant anti-TNF 
treatment. Reported CSy symptoms are summarized in table 3. 
 
Treatment for CSy was initiated in 10 patients (45.5%) with allmost all of them treated with 
systemic corticosteroids. 1 patient was treated with methotrexate alone, while 2 of the 
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other 9 patients were treated with cyclophosphamide and AZA, respectively, in addition to 
oral corticosteroids. Of those treated, 7 patients (70%) showed at least a partial response or 
stabilization of the disease with 1 additional patient still under therapy with response 
awaiting. Cochlea implantation was performed in a total of 4 patients. Laboratory testing 
was normal in most of the patients with abnormal, but only slightly elevated CRP in 7 
patients (mean 8.2 g/dl, range 1.4-18.0) and elevated blood sedimentation reaction in only 5 
patients (mean 56 mm/h, range 45-70).  
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Discussion 
CSy is a very rare autoimmune disease affecting the inner ear, which may ultimately result in 
complete (bilateral) deafness. [18] CSy typically affects young Caucasian adults [8] with a 
median age of 25 years at disease onset and without gender specific predilection, [19] which 
is in impressive contrast to the relatively older age (median age at CSy onset of 44.6 years) 
and female preponderance in this case series – even if the diagnostic delay of 1 year (with a 
maximum of 15 years) is taken into consideration.  Other autoimmune disorders occur in 15-
30% of CSy patients. [2] Up to date, only 13 patients have been reported with the 
concomitant diagnosis of IBD and CSy. In the vast majority the onset of CSy precedes IBD 
manifestation. [7,12] Herein, we report on 22 IBD patients, who were all diagnosed with CSy 
after IBD manifestation with a median time from IBD to CSy diagnosis of 8.7 years and a 
broad range of 0.0 years up to 38.0 years.  Little is known about this assocation between CSy 
and IBD and even less is known about its pathogenetic mechanisms. Given the extremely 
rare incidence of CSy with not exceeding 250 cases reported in the medical literature, [18] 
the identification of 22 IBD patients with concomitant CSy herein may suggest a stronger 
association between these two entities of dysregulated immunity than previously thought. 
However, as it is has been shown in several cases treated with anti-TNF for inflammatory 
diseases such as IBD or rheumatoid arthritis, [20-22] TNF antibodies themself may trigger 
neurologic symptoms, which may include CSy-like symptoms, via a demyelinating process 
comparable to multiple sclerosis. Nevertheless, none of the ongoing audiovestibular or other 
neurologic manifestations were attributed to anti-TNF in the 9 patients with prior or 
concomitant anti-TNF therapy. 
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CSy is thought to be an autoimmune disease that is mediated by a hypersensitivity response 
to infectious agents associated with vasculitis. [1,23,24] An immediate preceding upper 
respiratory tract infection may lead to cross-reactive auto-antibodies, in particular. 
Interestingly, some case reports could show elevated titres against C. trachomatis and C. 
pneumoniae. [10,25] However, in this case series only 2 patients reported prodrome 
symptoms of viral infection preceding CSy diagnosis. Several antibodies directed against 
corneal antigens and antigens on endothelial cells and in the inner ear have been identified. 
[1,16,26,27] One of them with reactivity against the Cogan-peptide, which shares sequence 
homology with CD148 and connexin 26 (expressed on endothelial cells and in the inner ear), 
is able to transfer the disease in animal models. [28] Moreover, histopathological 
examinations revealed a lymphocytic and plasma cell infiltration to the corneal and cochleal 
tissue suggesting a cell-mediated autoimmune reactivity. [29] This is further supported by 
the fact that CSy patients` lymphocytes are activated when exposed to corneal and inner ear 
antigens. [14,23,30] In contrast, IBD – with the two main subtypes CD and UC – is not 
regarded as a classical autoimmune disorder and its etiopathogenesis is yet incompletely 
understood. Nevertheless, it is considered to be a multifactorial disease, which arises from a 
complex interplay between genetic, environmental and immunological factors with an 
abnormal host immune response to environmental stimuli. [31] So far, no common 
pathogenetic mechanisms between CSy and IBD have been identified. To the best of our 
knowledge, there are no shared susceptibility genes, auto-antibodies or environmental 
factors. Interestingly, IBD disease activity does not seem to trigger CSy given the finding, that 
50% had quiescent CD or UC at CSy diagnosis in this case series. One may assume that the 
association between these entities is no more than a cluster of two disorders with a dys-
regulated immune system rather than one common underlying autoimmune process. 
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Success of CSy treatment depends on its early diagnosis and early initiation of systemic 
corticosteroids, which are considered first line treatment in the presence of inner ear 
pathology, severe inflammation of the eye and/or systemic vasculitis. [17] If treatment is 
started within the very first two weeks after hearing loss, more than 50% of the patients 
show some improvement, while only 8% will improve if treatment is started later. [10,19,32] 
Combination with other immunosuppressants such as cyclosporine or methotrexate may 
even improve disease course. [9,33,34] Recently, anti-TNF treatment (with infliximab in 
particular) has been reported to be of some effect. [35-38] However, this efficacy seems to 
be limited, which is consistent with our finding that 6 patients developed CSy during 
treatment with an anti-TNF antibody. Limited response rates of immunomodulatory 
treatment is also reflected in the fact that 16 patients were diagnosed with CSy despite IBD 
maintenance treatment. Given a relatively restrictive therapeutic approach in our 22 
patients with only 10 treated with immunomodulators, treatment success rate (70% partial 
response) was higher than in the literature. No anti-TNF treatment was performed. 
Remarkably, disease progression was observed in all other patients ultimately leading to uni- 
or even bilateral deafness in 13 of them with 4 patients requiring a cochlea implantation as 
ultima ratio.  
 
However, as suggested by Scharl et al, [9] association between CSy and IBD may be even 
stronger than previously thought. Given the rapid progression of CSy ultimately leading to 
(bilateral) deafness, one should consider this very rare diagnosis in IBD patients complaining 
of unspecific audiovestibular symptoms such as dizziness and hearing loss and/or ocular 
inflammation. Although CSy is considered to be an autoimmune disease, 
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immunomodulatory IBD maintenance treatment and even anti-TNF antibodies do not seem 
to prevent disease onset. Moreover, IBD disease activity does not seem to trigger CSy. 
However, early diagnosis is key and early initiation of systemic corticosteroids in selected 
patients may lead at least to a partial response and audiovestibular improvement. 
Otherwise, disease progresses rapidly ultimately leading to uni- or even bilateral deafness. In 
conclusion, vigilance may prompt early diagnosis and directed intervention with 
corticosteroids at inception may potentially hinder audiovestibular deterioration. Finally, 
vigilance and awareness may also offer a better setting to study the pathophysiological 
mechanisms of this rare, but debilitating phenomena. 
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 Mean (range), n=22 
Age (in years) 46.6 (19.0-74.0) 
Sex 
- female 
- male 
 
13 (59.1%) 
9 (40.9%) 
IBD (UC/CD) 6 (27.3%) / 16 (72.7%) 
Age at diagnosis (in years) 34.7 (1.0-59.0) 
Race 
- Caucasian 
- Asian 
- Black 
- Ashkenazi Jew 
 
18 (81.8%) 
1 (4.5%) 
1 (4.5%) 
1 4.5%) 
Geographic spread 
- Israel 
- Germany 
- Greece 
- Poland 
- Brasil 
- Denmark 
- Switzerland 
 
6 (27.3%) 
5 (22.7%) 
5 (22.7%) 
3 (13.6%) 
1 (4.5%) 
1 (4.5) 
1 (4.5%) 
Positive family history for IBD 2 (9.1%) 
Smoking: current/past/never 3 (13.6%) / 4 (18.2%) / 15 (68.2%) 
Prior surgery 8 (36.4%) 
Prior anti-TNF treatment 9 (40.9%) 
 
Table 1: Patient demographics and IBD characteristics 
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 Mean (range), n=22 
Mean age at diagnosis (in years) 44.6 (9.0-67.0) 
Time from first hearing impairment to CSy 
diagnosis (in years) 
1 (0-15) 
Time from IBD to CSy diagnosis 8.7 (0.0-38.0) 
Patients under IBD treatment at diagnosis 16 (72.7%) 
Patients under anti-TNF treatment at 
diagnosis 
6 (27.3%) 
Patients with active IBD at diagnosis 11 (50%) 
Treatment for CSy 10 (45.5%) 
 
Table 2: IBD and CSy characteristics 
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Symptoms Number of patients (n=22) 
Impaired hearing 18 (81.8%) 
Tinnitus 17 (77.3%) 
Hearing loss 16 (72.7%) 
Fatigue  16 (72.7%) 
Headache 15 (68.2%) 
Vertigo 13 (59.1%) 
Dizziness 13 (59.1%) 
Sensation of fullness of ear, ear pain 10 (45.5%) 
Arthralgia 10 (45.5%) 
Deafness (bilateral) 9 (40.9%) 
Interstitial keratitis 6 (31.8%) 
Meniére-like attacks 5 (22.7%) 
Myalgia 4 (18.2%) 
Conjunctivitis 3 (13.6%) 
Fever  3 (13.6%) 
Arthritis 3 (13.6%) 
 
Table 3: Frequency of CSy symptoms 
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Patient Sex Age IBD IBD 
(type) 
Disease 
extent 
IBD therapy 
before CS 
CS IBD to 
CS (in 
years) 
Audiologic 
symptoms 
Vestibular 
symptoms 
Ocular 
symptoms 
Under IBD 
treatment 
Active IBD at CS 
diagnosis 
1 m 56 56 CD A3, L1, B2 ASA, AZA   Bilateral deafness Menière Conjunctivitis none  
2 m 52 37 UC E2 ASA, 
Steroids 
43 5 Bilateral deafness Tinnitus, vertigo  ASA Active 
3 f 35 18 UC E1 ASA 34 1.25 Sudden hearing 
loss 
none  ASA, steroids Active 
4 f 64 59 CD A3, L3, B1 ASA, MTX, 
TNF 
64 5.5 Bilateral deafness Menière, 
tinnitus 
 TNF Quiescent 
5 f 40 25 CD A2, L1, B1 ASA, 
Steroids 
40 16 Bilateral hearing 
loss 
Meniére, 
tinnitus, vertigo 
 none Quiescent 
6 f 24 13 CD A1, L2, B3 ASA, 
Steroids, 
AZA, TNF (2) 
24 12 Deafness none  none Quiescent 
7 f 26 1 CD A1, L3, B2 ASA, 
Steroids, 
AZA, MTX, 
TNF 
 5 None Menière  none Quiescent 
8 m 59 57 CD A3, L1, B1 AZA 58 0.5 Bilateral deafness Menière, 
tinnitus, vertigo 
IK AZA Active 
9 f 64 46 CD A3, L1, B2 ASA, AZA 63 1.33 Sudden bilateral 
hearing loss 
Menière, 
tinnitus, vertigo 
 ASA Quiescent 
10 m 54 13 CD A1, L1, B3 ASA, 
Steroids, 
MTX, TNF 
(2) 
52 38 Bilateral deafness Menière, 
tinnitus, vertigo 
 TNF Active 
11 f 19 7 CD A1, L4, B2 ASA 9 3 Bilateral deafness unkown  ASA Active 
12 m 61 44 CD A3, L3, B3 ASA, 
Steroids, 
TNF 
61 16 Sudden hearing 
impairment 
vertigo IK, 
conjunctivitis 
TNF Active 
13 m 39 39 CD A2, L1, B1 none 38 0 Deafness Menière  none Active 
14 f 45 49 CD A2, L3, B2 ASA, AZA, 
TNF 
44 4 Deafness Menière, 
vertigo 
IK, 
conjunctivitis 
ASA Quiescent 
15 f 56 50 CD A3, L2, B1 ASA, 
Steroids 
54 4 Deafness none IK ASA Quiescent 
16 m 74 55 UC E3 ASA, 
Steroids, 
AZA 
67 21 Hearing loss Menière IK ASA, steroids Active 
17 f 43 39 CD A2, L3, B2 ASA, 43 5 Bilateral deafness Menière,  TNF Quiescent 
Steroids, 
AZA, MTX, 
TNF 
vertigo 
18 m 40 32 CD A2, L1, B1 Steroids, 
AZA, MTX, 
TNF (2) 
40 7 Deafness Menière  AZA, TNF Quiescent 
19 m 29 26 CD A2, L3, B3 TNF 27 1 Ear pain Menière scleritis TNF Active 
20 f 46 36 UC E3 ASA, 
Steroids, 
AZA, MTX 
40 4 Ear pain Menière IK, 
progressive 
worsening of 
visual sense 
ASA, 
Budesonide 
Active 
21 f 52 44 UC E3 ASA, 
Steroids, 
AZA 
51 11 Deafness Menière  NA  
22 f 48 17 UC E3 Steroids, 
AZA 
39 22 Ear pain Menière, 
vertigo 
IK AZA Active 
Supplementary Table 1: Patient characteristics of the 22 described patients. The columns IBD and CS indicate the year, when the respective 
diagnosis was established. Abbreviations: m=male; f=female; UC=ulcerative colitis; CD=Crohn`s disease; ASA=5-aminosalicylic acid, 
AZA=azathioprine; MTX=methotrexate; TNF=anti-TNF therapy     
